SEARCH

SEARCH BY CITATION

References

  • 1
    Maestro MA, Cardalda C, Boj SF, Luco RF, Servitja JM, Ferrer J. Distinct roles of HNF1 beta, HNF1 alpha, and HNF4 alpha in regulating pancreas development, beta -cell function and growth. Endocr Dev 2007; 12: 3345.
  • 2
    Wang H, Maechler P, Antinozzi PA, Hagenfeldt KA, Wollheim CB. Hepatocyte nuclear factor 4alpha regulates the expression of pancreatic beta-cell genes implicated in glucose metabolism and nutrient-induced insulin secretion. J Biol Chem 2000; 275: 3595335959.
  • 3
    Ryffel, GU. Mutations in the human genes encoding the transcription factors of the hepatocyte nuclear factor (HNF)1 and HNF4 families: functional and pathological consequences. J Mol Endocrinol 2001; 27: 1129.
  • 4
    Tirona RG, Lee W, Leake BF, Lan LB, Cline CB, Lamba V, et al. The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med 2003; 9: 220224.
  • 5
    Martinez-Jimenez CP, Castell JV, Gomez-Lechon MJ, Jover R. Transcriptional activation of CYP2C9, CYP1A1, and CYP1A2 by hepatocyte nuclear factor 4alpha requires coactivators peroxisomal proliferator activated receptor-gamma coactivator 1alpha and steroid receptor coactivator 1. Mol Pharmacol 2006; 70: 16811692.
  • 6
    Ferguson SS, Chen Y, LeCluyse EL, Negishi M, Goldstein JA. Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha. Mol Pharmacol 2005; 68: 747757.
  • 7
    Ibeanu GC, Goldstein JA. Transcriptional regulation of human CYP2C genes: functional comparison of CYP2C9 and CYP2C18 promoter regions. Biochemistry 1995; 34: 80288036.
  • 8
    Cairns W, Smith CA, McLaren AW, Wolf CR. Characterization of the human cytochrome P4502D6 promoter: a potential role for antagonistic interactions between members of the nuclear receptor family. J Biol Chem 1996; 271: 2526925276.
  • 9
    Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, et al. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 2003; 31: 421431.
  • 10
    Eichelbaum M, Mineshita S, Ohnhaus EE, Zekorn C. The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Pharmacol 1986; 22: 4953.
  • 11
    Corchero J, Granvil CP, Akiyama TE, Hayhurst GP, Pimprale S, Feigenbaum L, et al. The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. Mol Pharmacol 2001; 60: 12601267.
  • 12
    Daly AK. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol 2003; 17: 2741.
  • 13
    Lee SS, Jeong HE, Liu KH, Ryu JY, Moon T, Yoon CN, et al. Identification and functional characterization of novel CYP2J2 variants: G312R variant causes loss of enzyme catalytic activity. Pharmacogenet Genomics 2005; 15: 105113.
  • 14
    Lee SS, Kim KM, Thi-Le H, Yea SS, Cha IJ, Shin JG. Genetic polymorphism of CYP2C9 in a Vietnamese Kinh population. Ther Drug Monit 2005; 27: 208210.
  • 15
    Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263265.
  • 16
    Maeda Y, Seidel SD, Wei G, Liu X, Sladek FM. Repression of hepatocyte nuclear factor 4alpha tumor suppressor p53: involvement of the ligand-binding domain and histone deacetylase activity. Mol Endocrinol 2002; 16: 402410.
  • 17
    Eeckhoute J, Oxombre B, Formstecher P, Lefebvre P, Laine B. Critical role of charged residues in helix 7 of the ligand binding domain in Hepatocyte Nuclear Factor 4alpha dimerisation and transcriptional activity. Nucl Acids Res 2003; 31: 66406650.
  • 18
    Frank D, Jaehde U, Fuhr U. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol 2007; 63: 321333.
  • 19
    Eichhold TH, Greenfield LJ, Hoke SH 2nd, Wehmeyer KR. Determination of dextromethorphan and dextrorphan in human plasma by liquid chromatography/tandem mass spectrometry. J Mass Spectrom 1997; 32: 12051211.
  • 20
    Bartoletti RA, Belpaire FM, Rosseel MT. High performance liquid chromatography determination of dextromethorphan and its metabolites in urine using solid-phase extraction. J Pharm Biomed Anal 1996; 14: 12811286.
  • 21
    Kamiyama Y, Matsubara T, Yoshinari K, Nagata K, Kamimura H, Yamazoe Y. Role of human hepatocyte nuclear factor 4alpha in the expression of drug-metabolizing enzymes and transporters in human hepatocytes assessed by use of small interfering RNA. Drug Metab Pharmacokinet 2007; 22: 287298.
  • 22
    Chen WS, Manova K, Weinstein DC, Duncan SA, Plump AS, Prezioso VR, et al. Disruption of the HNF-4 gene, expressed in visceral endoderm, leads to cell death in embryonic ectoderm and impaired gastrulation of mouse embryos. Genes Dev 1994; 8: 24662477.
  • 23
    Parviz F, Matullo C, Garrison WD, et al. Hepatocyte nuclear factor 4alpha controls the development of a hepatic epithelium and liver morphogenesis. Nat Genet 2003; 34: 292296.
  • 24
    Battle MA, Konopka G, Parviz F, et al. Hepatocyte nuclear factor 4alpha orchestrates expression of cell adhesion proteins during the epithelial transformation of the developing liver. Proc Natl Acad Sci U S A 2006; 103: 84198424.
  • 25
    Price JA, Fossey SC, Sale MM, Brewer CS, Freedman BI, Wuerth JP, et al. Analysis of the HNF4 alpha gene in Caucasian type II diabetic nephropathic patients. Diabetologia 2000; 43: 364372.
  • 26
    Ek J, Rose CS, Jensen DP, Glümer C, Borch-Johnsen K, Jørgensen T, et al. The functional Thr130Ile and Val255Met polymorphisms of the hepatocyte nuclear factor-4alpha (HNF4A): gene associations with type 2 diabetes or altered beta-cell function among Danes. J Clin Endocrinol Metab 2005; 90: 30543059.